<?xml version="1.0" encoding="UTF-8"?>
<p>Multicenter clinical trials in China showed that chloroquine was effective and had an acceptable safety profile in patients with SARS-CoV-2 pneumonia (
 <xref rid="B91" ref-type="bibr">91</xref>). Hydroxychloroquine is currently under investigation in various RCTs in the Unites States for treatment in patients with SARS-CoV-2 infection and also for pre-exposure and post-exposure prophylaxis. In one retrospective cohort study involving 1,438 patients hospitalized in metropolitan New York, treatment with hydroxychloroquine, azithromycin, or both was not associated with significantly lower in-hospital mortality when compared to neither treatment. However, the interpretation of these findings may be limited by the observational design (
 <xref rid="B92" ref-type="bibr">92</xref>).
</p>
